Benefit/risk of cyclosporine in rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 15552522
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological effects of cyclosporin A: A new antilymphocytic agent

  2005cited by this paper
• Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression.

  2004cited by this paper
• SUPPRESSION OF CYCLOSPORINE A NEPHROTOXICITY IN VIVO BY TRANSFORMING GROWTH FACTOR β RECEPTOR-IMMUNOGLOBULIN G CHIMERIC PROTEIN

  2004cited by this paper
• Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.

  2003cited by this paper
• Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine.

  2003cited by this paper
• Cyclosporine nephrotoxicity.

  2003cited by this paper
• Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial

  2003cited by this paper
• Cyclosporine A in treatment of membranous lupus nephropathy.

  2003cited by this paper
• Amelioration of cyclosporin A effect on microvasculature by endothelin inhibitor.

  2003cited by this paper
• The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials.

  2003cited by this paper
• Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.

  2003cited by this paper
• Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

  2002cited by this paper
• Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension

  2002cited by this paper
• Interaction of cyclosporine A and the renin-angiotensin system; new perspectives.

  2002cited by this paper
• Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis.

  2002cited by this paper
• Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis

  2002cited by this paper
• Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts.

  2002cited by this paper
• Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes.

  2002cited by this paper
• Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years.

  2002cited by this paper
• Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney.

  2002cited by this paper
• Inhibition of neutrophil responses by cyclosporin A. An insight into molecular mechanisms.

  2001cited by this paper
• “Stepping-up” from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate

  2001cited by this paper
• Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study.

  2001cited by this paper
• Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.

  2001cited by this paper
• Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome

  2001cited by this paper
• Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies

  2001cited by this paper
• IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis

  2001cited by this paper
• Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a

  2001cited by this paper
• Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.

  2000cited by this paper
• A role for leukotrienes in cyclosporine nephrotoxicity.

  2000cited by this paper
• Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.

  2000cited by this paper
• Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study

  2000cited by this paper
• Enalaprilat Directly Ameliorates in vitro Cyclosporin Nephrotoxicity in Human Tubulo-Interstitial Cells

  2000cited by this paper
• Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.

  2000cited by this paper
• Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding.

  1999cited by this paper
• Cyclosporin A therapy in rheumatoid arthritis: only strict application of the guidelines for safe use can prevent irreversible renal function loss.

  1999cited by this paper
• US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis.

  1999cited by this paper
• Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium.

  1999cited by this paper
• Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow.

  1999cited by this paper
• Renal toxicity of long-term cyclosporin.

  1999cited by this paper
• IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

  1999cited by this paper
• Interleukin-10 Signaling Blocks Inhibitor of κB Kinase Activity and Nuclear Factor κB DNA Binding*

  1999cited by this paper
• Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold.

  1998cited by this paper
• A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases.

  1998cited by this paper
• Comparative study of cyclosporin A, cyclosporin G, and the novel cyclosporin derivative IMM 125 in isolated glomeruli and cultured rat mesangial cells: a morphometric analysis.

  1998cited by this paper
• Effect of 1 year cyclosporine a treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study

  1998cited by this paper
• Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.

  1998cited by this paper
• Long-term treatment of lupus nephritis with cyclosporin A.

  1998cited by this paper
• IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.

  1998cited by this paper
• Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy.

  1998cited by this paper
• Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis.

  1998cited by this paper
• Cyclosporin A in the treatment of adult onset Still's disease.

  1997cited by this paper
• The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review.

  1997cited by this paper
• Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis.

  1997cited by this paper
• Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts.

  1997cited by this paper
• Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells.

  1997cited by this paper
• Cyclosporin A interferes with the inducible degradation of NF‐xB inhibitors, but not with the processing of p105/NF‐xB1 in T cells

  1997cited by this paper
• Tissue cytokine patterns distinguish variants of rheumatoid synovitis.

  1997cited by this paper
• Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry.

  1996cited by this paper
• Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study.

  1996cited by this paper
• Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy.

  1996cited by this paper
• The role of interleukin–15 in T–cell migration and activation in rheumatoid arthritis

  1996cited by this paper
• Longterm low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy.

  1996cited by this paper
• Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A.

  1996cited by this paper
• Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.

  1996cited by this paper
• Human IL-17: a novel cytokine derived from T cells.

  1995cited by this paper
• Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis.

  1995cited by this paper
• Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients.

  1995cited by this paper
• Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.

  1995cited by this paper
• Inhibition of phagocytes by cyclosporin in vitro.

  1994cited by this paper
• Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue

  1994cited by this paper
• Mechanism of cyclosporine-induced sympathetic activation and acute hypertension in rats.

  1994cited by this paper
• Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group.

  1994cited by this paper
• Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis.

  1994cited by this paper
• Mechanisms of the endothelial toxicity of cyclosporin A. Role of nitric oxide, cGMP, and Ca2+.

  1994cited by this paper
• Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies).

  1994cited by this paper
• Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis — Results of a double-blind multicentre study

  1994cited by this paper
• Effect of transforming growth factor-beta on early and late activation events in human T cells.

  1993cited by this paper
• The mechanism of action of cyclosporin A and FK506.

  1992cited by this paper
• Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis.

  1992cited by this paper
• Consensus Conference on cyclosporin A for psoriasis February 1992

  1992cited by this paper
• Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.

  1992cited by this paper
• Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal Transduction

  1992cited by this paper
• IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

  1991cited by this paper
• The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies.

  1991cited by this paper
• A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis.

  1991cited by this paper
• A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis.

  1991cited by this paper
• Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study.

  1991cited by this paper
• Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

  1990cited by this paper
• Stimulatory effect of cyclosporine A on endothelin secretion by a cultured renal epithelial cell line, LLC-PK1 cells.

  1990cited by this paper
• Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis.

  1989cited by this paper
• Ciclosporin in the treatment of lupus nephritis.

  1989cited by this paper
• The place of cyclosporine A in the treatment of connective tissue diseases.

  1988cited by this paper
• ASSOCIATIONS BETWEEN CYCLOSPORINE THERAPY AND INTERSTITIAL FIBROSIS IN RENAL ALLOGRAFT BIOPSIES1,2

  1988cited by this paper
• In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A

  1988cited by this paper
• CYCLOSPORINE SUPPRESSION OF ENDOTHELIAL PROSTACYCLIN GENERATION: A POSSIBLE MECHANISM FOR NEPHROTOXICITY

  1988cited by this paper
• An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report.

  1987cited by this paper
• Cyclosporin A treatment of refractory rheumatoid arthritis.

  1987cited by this paper
• Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial.

  1987cited by this paper
• Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function.

  1987cited by this paper

• EIDD-1931 Treatment Tweaks CYP3A4 and CYP2C8 in Arthritic Rats to Expedite Drug Interaction: Implication in Oral Therapy of Molnupiravir

  2024cites this paper
• Supra-lacrimal protein-based carriers for cyclosporine A reduce Th17-mediated autoimmunity in murine model of Sjögren's syndrome.

  2022cites this paper
• Molecular mechanisms and therapeutic target of NETosis in diseases

  2022cites this paper
• Compounded medications for ocular surface disease

  2021cites this paper
• Antioxidant and Anti-Inflammatory Effects of Bischofia javanica (Blume) Leaf Methanol Extracts through the Regulation of Nrf2 and TAK1

  2021cites this paper
• The Role of Neutrophil NETosis in Organ Injury: Novel Inflammatory Cell Death Mechanisms

  2020cites this paper
• Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?

  2020cites this paper
• Metalloimmunology: The metal ion-controlled immunity.

  2020cites this paper
• Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics

  2019cites this paper
• Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial

  2019cites this paper
• Gene expression and micro RNA profiling in acute pancreatitis

  2018cites this paper
• Pathogenesis, Clinical Syndromology and Treatment of Rheumatoid Arthritis

  2017cites this paper
• TFOS DEWS II Management and Therapy Report.

  2017cites this paper
• The Effects of Immunosuppressive and Cytotoxic Drugs on the Heart

  2017cites this paper
• Dosierung und Toxizität von Antirheumatika bei Niereninsuffizienz

  2015cites this paper
• Regulation of cyclosporin A and methotrexate on IL-17 expression in the treatment of rheumatoid arthritis

  2015cites this paper
• Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: size does not matter.

  2015cites this paper
• Functional aspects of extracellular cyclophilins

  2014cites this paper
• NFATc2 mediates epigenetic modification of dendritic cell cytokine and chemokine responses to dectin-1 stimulation

  2014cites this paper
• Pharmacokinetic Interaction Study of Ticagrelor and Cyclosporine in Healthy Volunteers

  2014cites this paper
• Efficient Neutrophil Extracellular Trap Induction Requires Mobilization of Both Intracellular and Extracellular Calcium Pools and Is Modulated by Cyclosporine A

  2014cites this paper
• Nuclear factor of activated T cells—A transcription factor family as critical regulator in lung and colon cancer

  2014cites this paper
• Role of the Actin Cytoskeleton in Pro-fibrotic Signaling

  2012cites this paper
• Tacrolimus in Patients with Rheumatoid Arthritis

  2012influential citation
• ANÁLISIS DE LA VARIACIÓN DE LOS COSTOS DE LOS MEDICAMENTOS DE ARTRITIS REUMATOIDE EN UNA EPS EN LA CIUDAD DE BOGOTÁ, 2009 - 2011

  2011cites this paper
• The Mucocutaneous Manifestations and Pathergy Reaction in Behçet’s Disease

  2010cites this paper
• The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study

  2010cites this paper
• Calf thymus extract attenuates severity of experimental encephalomyelitis in Lewis rats.

  2010cites this paper
• Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial

  2009cites this paper
• Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

  2009cites this paper
• High-frequency Topical Cyclosporine 0.05% in the Treatment of Severe Dry Eye Refractory to Twice-daily Regimen

  2009cites this paper
• Topical ophthalmic cyclosporine: pharmacology and clinical uses.

  2009cites this paper
• Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease.

  2008cites this paper
• Renal manifestation in patients with rheumatoid arthritis

  2008cites this paper
• 류마티스관절염에서 발생하는 신장 증상

  2008cites this paper
• Methotrexate and Cyclosporine Treatments Modify the Activities of Dipeptidyl Peptidase IV and Prolyl Oligopeptidase in Murine Macrophages

  2008cites this paper
• The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis

  2007cites this paper
• UR-1505, a New Salicylate, Blocks T Cell Activation through Nuclear Factor of Activated T Cells

  2007cites this paper
• Cyclosporin inhibition of collagen remodeling is mediated by gelsolin.

  2007cites this paper
• The Cathepsin B Inhibitor, z-FA-FMK, Inhibits Human T Cell Proliferation In Vitro and Modulates Host Response to Pneumococcal Infection In Vivo1

  2006cites this paper
• Pediatric rheumatology Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study

  2006cites this paper
• Topical Cyclosporine for Treatment of Ocular Surface Disease

  2006cites this paper
• Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study.

  2006cites this paper
• Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases.

  2006cites this paper
• The role and regulation of caspases during T cell activation and proliferation

  2006cites this paper
• Renal and macrophage aminopeptidase activities in cyclosporin-treated mice.

  2006cites this paper
• Pneumococcal Infection In Vivo and Modulates Host Response to Inhibits Human T Cell Proliferation In Vitro The Cathepsin B Inhibitor , zFA-FMK

  2006cites this paper
• Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease.

  2006cites this paper
• Basic immunosuppressive drugs outside solid organ transplantation

  2006cites this paper
• NFAT proteins: key regulators of T-cell development and function

  2005cites this paper
• Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis.

  2005cites this paper
• Cyclosporine: From Renal Transplantation to Autoimmune Diseases

  2005cites this paper
• From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials?

  2005cites this paper
• Failure of unicondylar knee replacement in a patient with psoriatic arthropathy

  2005cites this paper
• Management Issues with Elderly-Onset Rheumatoid Arthritis

  2005cites this paper